Financials data is unavailable for this security.
View more
Year on year SCI Pharmtech Inc had net income fall -4.55% from 308.78m to 294.72m despite a 33.83% increase in revenues from 899.74m to 1.20bn. An increase in the cost of goods sold as a percentage of sales from 67.64% to 70.91% was a component in the falling net income despite rising revenues.
| Gross margin | 27.75% |
|---|---|
| Net profit margin | 11.06% |
| Operating margin | 11.60% |
| Return on assets | 2.26% |
|---|---|
| Return on equity | 3.02% |
| Return on investment | 2.54% |
More ▼
Cash flow in TWDView more
In 2023, SCI Pharmtech Inc increased its cash reserves by 464.69%, or 775.23m. Cash Flow from Financing totalled 1.43bn or 118.40% of revenues. In addition the company generated 215.77m in cash from operations while cash used for investing totalled 866.20m.
| Cash flow per share | 3.35 |
|---|---|
| Price/Cash flow per share | 32.12 |
| Book value per share | 42.26 |
|---|---|
| Tangible book value per share | 41.91 |
More ▼
Balance sheet in TWDView more
| Current ratio | 2.59 |
|---|---|
| Quick ratio | 1.78 |
| Total debt/total equity | 0.2235 |
|---|---|
| Total debt/total capital | 0.1826 |
More ▼
Growth rates in TWD
Year on year, growth in dividends per share increased 473.42% while earnings per share excluding extraordinary items fell by -4.46%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.49% |
|---|---|
| Div growth rate (5 year) | -16.35% |
| Payout ratio (TTM) | 107.89% |
| EPS growth(5 years) | -7.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -68.15 |
More ▼
